{"entity":{"type":"insider","cik":"0001404570","url":"/insider/0001404570","json_url":"/insider/0001404570.json","name":"Invus, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":44,"n_filings":23,"first":"2007-08-24","last":"2023-06-05","span_basis":"filed_date"},"name_variants":[{"name":"Invus, L.P.","source":"filing","n_filings":23,"first_seen":"2007-08-24","last_seen":"2023-06-05"}],"transactions":[{"id":8569558,"accession":"0000899243-23-014464","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-014464","line_url":"/filing/0000899243-23-014464#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International S.C.A.; Invus Advisors, L.L.C.; Westend S.A.; Wittouck Amaury; Stichting Administratiekantoor Westend; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Invus, L.P.; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International S.C.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27775050.0,"shares_display":"27,775,050","price_per_share":2.6,"price_display":"2.60","price_state":"stated","total_value":72215130.0,"total_display":"72,215,130.00","total_whole":"72,215,130","shares_owned_after":78634381.0,"shares_owned_after_display":"78,634,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-05","filed_date":"2023-06-05","scope":"insider"},{"id":6386319,"accession":"0000899243-22-028108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-028108","line_url":"/filing/0000899243-22-028108#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus, L.P.; Stichting Administratiekantoor Westend; Invus Advisors, L.L.C.; Artal International S.C.A.; Wittouck Amaury; Invus Public Equities Advisors, LLC; Westend S.A.; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2426070.0,"shares_display":"2,426,070","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":6065175.0,"total_display":"6,065,175.00","total_whole":"6,065,175","shares_owned_after":50859331.0,"shares_owned_after_display":"50,859,331","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-05","filed_date":"2022-08-09","scope":"insider"},{"id":6741599,"accession":"0000899243-22-027156","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-027156","line_url":"/filing/0000899243-22-027156#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Westend S.A.; Invus, L.P.; Artal Group S.A.; Stichting Administratiekantoor Westend; Artal International S.C.A.; Artal International Management S.A.; Wittouck Amaury; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16173800.0,"shares_display":"16,173,800","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":40434500.0,"total_display":"40,434,500.00","total_whole":"40,434,500","shares_owned_after":48433261.0,"shares_owned_after_display":"48,433,261","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-01","filed_date":"2022-08-01","scope":"insider"},{"id":3204093,"accession":"0000899243-20-034268","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-034268","line_url":"/filing/0000899243-20-034268#line-1","is_derivative":false,"issuer_cik":"0001062822","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001062822","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal Treasury Ltd; Invus Public Equities Advisors, LLC; Invus, L.P.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10937500.0,"shares_display":"10,937,500","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":35000000.0,"total_display":"35,000,000.00","total_whole":"35,000,000","shares_owned_after":32259461.0,"shares_owned_after_display":"32,259,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-16","filed_date":"2020-12-17","scope":"insider"},{"id":6646985,"accession":"0000899243-18-018727","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-018727","line_url":"/filing/0000899243-18-018727#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus, L.P.; Minne Pascal; Stichting Administratiekantoor Westend; Artal International S.C.A.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Advisors, L.L.C.; Artal Group S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57724.0,"shares_display":"57,724","price_per_share":12.4547,"price_display":"12.45","price_state":"stated","total_value":718935.1028,"total_display":"718,935.10","total_whole":"718,935","shares_owned_after":3516214.0,"shares_owned_after_display":"3,516,214","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-28","filed_date":"2018-06-29","scope":"insider"},{"id":6646981,"accession":"0000899243-18-018727","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-018727","line_url":"/filing/0000899243-18-018727#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus, L.P.; Minne Pascal; Stichting Administratiekantoor Westend; Artal International S.C.A.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Advisors, L.L.C.; Artal Group S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125114.0,"shares_display":"125,114","price_per_share":12.5361,"price_display":"12.54","price_state":"stated","total_value":1568441.6154,"total_display":"1,568,441.62","total_whole":"1,568,442","shares_owned_after":3458490.0,"shares_owned_after_display":"3,458,490","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-27","filed_date":"2018-06-29","scope":"insider"},{"id":6250830,"accession":"0000899243-18-018161","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-018161","line_url":"/filing/0000899243-18-018161#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Westend S.A.; Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Public Equities, L.P.; Invus, L.P.; Stichting Administratiekantoor Westend; Artal Group S.A.; Artal International S.C.A.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":228264.0,"shares_display":"228,264","price_per_share":12.9459,"price_display":"12.95","price_state":"stated","total_value":2955082.9176,"total_display":"2,955,082.92","total_whole":"2,955,083","shares_owned_after":3333376.0,"shares_owned_after_display":"3,333,376","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-25","filed_date":"2018-06-26","scope":"insider"},{"id":6250827,"accession":"0000899243-18-018161","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-018161","line_url":"/filing/0000899243-18-018161#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Westend S.A.; Invus Advisors, L.L.C.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Invus Public Equities, L.P.; Invus, L.P.; Stichting Administratiekantoor Westend; Artal Group S.A.; Artal International S.C.A.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25461.0,"shares_display":"25,461","price_per_share":13.3573,"price_display":"13.36","price_state":"stated","total_value":340090.2153,"total_display":"340,090.22","total_whole":"340,090","shares_owned_after":3105112.0,"shares_owned_after_display":"3,105,112","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-22","filed_date":"2018-06-26","scope":"insider"},{"id":6467164,"accession":"0000899243-18-017617","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":51600.0,"shares_display":"51,600","price_per_share":13.2677,"price_display":"13.27","price_state":"stated","total_value":684613.32,"total_display":"684,613.32","total_whole":"684,613","shares_owned_after":3079651.0,"shares_owned_after_display":"3,079,651","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-21","filed_date":"2018-06-21","scope":"insider"},{"id":6467162,"accession":"0000899243-18-017617","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12391.0,"shares_display":"12,391","price_per_share":13.2849,"price_display":"13.28","price_state":"stated","total_value":164613.1959,"total_display":"164,613.20","total_whole":"164,613","shares_owned_after":3028051.0,"shares_owned_after_display":"3,028,051","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-20","filed_date":"2018-06-21","scope":"insider"},{"id":6467157,"accession":"0000899243-18-017617","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-017617","line_url":"/filing/0000899243-18-017617#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Artal International Management S.A.; Invus Public Equities Advisors, LLC; Minne Pascal; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8982.0,"shares_display":"8,982","price_per_share":13.4512,"price_display":"13.45","price_state":"stated","total_value":120818.6784,"total_display":"120,818.68","total_whole":"120,819","shares_owned_after":3015660.0,"shares_owned_after_display":"3,015,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-19","filed_date":"2018-06-21","scope":"insider"},{"id":6217031,"accession":"0000899243-18-017071","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-017071","line_url":"/filing/0000899243-18-017071#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Stichting Administratiekantoor Westend; Minne Pascal; Artal International Management S.A.; Artal International S.C.A.; Invus Advisors, L.L.C.; Artal Group S.A.; Westend S.A.; Invus, L.P.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Stichting Administratiekantoor Westend","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":36584.0,"shares_display":"36,584","price_per_share":13.0641,"price_display":"13.06","price_state":"stated","total_value":477937.0344,"total_display":"477,937.03","total_whole":"477,937","shares_owned_after":3006678.0,"shares_owned_after_display":"3,006,678","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-18","filed_date":"2018-06-18","scope":"insider"},{"id":6217026,"accession":"0000899243-18-017071","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-017071","line_url":"/filing/0000899243-18-017071#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Stichting Administratiekantoor Westend; Minne Pascal; Artal International Management S.A.; Artal International S.C.A.; Invus Advisors, L.L.C.; Artal Group S.A.; Westend S.A.; Invus, L.P.; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Stichting Administratiekantoor Westend","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9200.0,"shares_display":"9,200","price_per_share":12.6589,"price_display":"12.66","price_state":"stated","total_value":116461.88,"total_display":"116,461.88","total_whole":"116,462","shares_owned_after":2970094.0,"shares_owned_after_display":"2,970,094","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-14","filed_date":"2018-06-18","scope":"insider"},{"id":5955480,"accession":"0000899243-18-016245","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-016245","line_url":"/filing/0000899243-18-016245#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus, L.P.; Invus Public Equities Advisors, LLC; Minne Pascal; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Invus Advisors, L.L.C.; Stichting Administratiekantoor Westend; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":107023.0,"shares_display":"107,023","price_per_share":12.8313,"price_display":"12.83","price_state":"stated","total_value":1373244.2199,"total_display":"1,373,244.22","total_whole":"1,373,244","shares_owned_after":2960894.0,"shares_owned_after_display":"2,960,894","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-12","filed_date":"2018-06-12","scope":"insider"},{"id":5955479,"accession":"0000899243-18-016245","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-016245","line_url":"/filing/0000899243-18-016245#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus, L.P.; Invus Public Equities Advisors, LLC; Minne Pascal; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Invus Advisors, L.L.C.; Stichting Administratiekantoor Westend; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":98626.0,"shares_display":"98,626","price_per_share":12.7497,"price_display":"12.75","price_state":"stated","total_value":1257451.9122,"total_display":"1,257,451.91","total_whole":"1,257,452","shares_owned_after":2853871.0,"shares_owned_after_display":"2,853,871","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-11","filed_date":"2018-06-12","scope":"insider"},{"id":5955474,"accession":"0000899243-18-016245","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-016245","line_url":"/filing/0000899243-18-016245#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus, L.P.; Invus Public Equities Advisors, LLC; Minne Pascal; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Invus Advisors, L.L.C.; Stichting Administratiekantoor Westend; Artal Group S.A.; Invus Public Equities, L.P.","owner_display_name":"Invus, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":29747.0,"shares_display":"29,747","price_per_share":12.8896,"price_display":"12.89","price_state":"stated","total_value":383426.9312,"total_display":"383,426.93","total_whole":"383,427","shares_owned_after":2755245.0,"shares_owned_after_display":"2,755,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-08","filed_date":"2018-06-12","scope":"insider"},{"id":6282906,"accession":"0000899243-18-015606","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-015606","line_url":"/filing/0000899243-18-015606#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Minne Pascal; Invus Advisors, L.L.C.; Artal International Management S.A.; Artal International S.C.A.","owner_display_name":"Invus Public Equities Advisors, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":57439.0,"shares_display":"57,439","price_per_share":12.9269,"price_display":"12.93","price_state":"stated","total_value":742508.2091,"total_display":"742,508.21","total_whole":"742,508","shares_owned_after":2725498.0,"shares_owned_after_display":"2,725,498","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-07","filed_date":"2018-06-07","scope":"insider"},{"id":6282904,"accession":"0000899243-18-015606","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-015606","line_url":"/filing/0000899243-18-015606#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Minne Pascal; Invus Advisors, L.L.C.; Artal International Management S.A.; Artal International S.C.A.","owner_display_name":"Invus Public Equities Advisors, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":95079.0,"shares_display":"95,079","price_per_share":12.5829,"price_display":"12.58","price_state":"stated","total_value":1196369.5491,"total_display":"1,196,369.55","total_whole":"1,196,370","shares_owned_after":2668059.0,"shares_owned_after_display":"2,668,059","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-06","filed_date":"2018-06-07","scope":"insider"},{"id":6282901,"accession":"0000899243-18-015606","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-015606","line_url":"/filing/0000899243-18-015606#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities Advisors, LLC; Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus, L.P.; Artal Group S.A.; Westend S.A.; Minne Pascal; Invus Advisors, L.L.C.; Artal International Management S.A.; Artal International S.C.A.","owner_display_name":"Invus Public Equities Advisors, LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":173121.0,"shares_display":"173,121","price_per_share":12.4548,"price_display":"12.45","price_state":"stated","total_value":2156187.4308,"total_display":"2,156,187.43","total_whole":"2,156,187","shares_owned_after":2572980.0,"shares_owned_after_display":"2,572,980","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-05","filed_date":"2018-06-07","scope":"insider"},{"id":6678069,"accession":"0000899243-18-014948","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-014948","line_url":"/filing/0000899243-18-014948#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Minne Pascal; Artal Group S.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Invus, L.P.; Artal International Management S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":121803.0,"shares_display":"121,803","price_per_share":12.2376,"price_display":"12.24","price_state":"stated","total_value":1490576.3928,"total_display":"1,490,576.39","total_whole":"1,490,576","shares_owned_after":2399859.0,"shares_owned_after_display":"2,399,859","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-04","filed_date":"2018-06-04","scope":"insider"},{"id":6678065,"accession":"0000899243-18-014948","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-014948","line_url":"/filing/0000899243-18-014948#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Minne Pascal; Artal Group S.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Invus, L.P.; Artal International Management S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":147339.0,"shares_display":"147,339","price_per_share":12.217,"price_display":"12.22","price_state":"stated","total_value":1800040.563,"total_display":"1,800,040.56","total_whole":"1,800,041","shares_owned_after":2278056.0,"shares_owned_after_display":"2,278,056","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-01","filed_date":"2018-06-04","scope":"insider"},{"id":6678061,"accession":"0000899243-18-014948","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-014948","line_url":"/filing/0000899243-18-014948#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Minne Pascal; Artal Group S.A.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Invus, L.P.; Artal International Management S.A.","owner_display_name":"Westend S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":147339.0,"shares_display":"147,339","price_per_share":11.6198,"price_display":"11.62","price_state":"stated","total_value":1712049.7122,"total_display":"1,712,049.71","total_whole":"1,712,050","shares_owned_after":2130717.0,"shares_owned_after_display":"2,130,717","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-31","filed_date":"2018-06-04","scope":"insider"},{"id":6113467,"accession":"0000899243-18-014494","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-014494","line_url":"/filing/0000899243-18-014494#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus Public Equities, L.P.; Artal Group S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Stichting Administratiekantoor Westend; Westend S.A.; Minne Pascal; Invus, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":147339.0,"shares_display":"147,339","price_per_share":10.3233,"price_display":"10.32","price_state":"stated","total_value":1521024.6987,"total_display":"1,521,024.70","total_whole":"1,521,025","shares_owned_after":1983378.0,"shares_owned_after_display":"1,983,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-30","filed_date":"2018-05-30","scope":"insider"},{"id":6113465,"accession":"0000899243-18-014494","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-014494","line_url":"/filing/0000899243-18-014494#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus Public Equities, L.P.; Artal Group S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Stichting Administratiekantoor Westend; Westend S.A.; Minne Pascal; Invus, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":147339.0,"shares_display":"147,339","price_per_share":9.8441,"price_display":"9.84","price_state":"stated","total_value":1450419.8499,"total_display":"1,450,419.85","total_whole":"1,450,420","shares_owned_after":1836039.0,"shares_owned_after_display":"1,836,039","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-29","filed_date":"2018-05-30","scope":"insider"},{"id":6113461,"accession":"0000899243-18-014494","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-014494","line_url":"/filing/0000899243-18-014494#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus Public Equities, L.P.; Artal Group S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Stichting Administratiekantoor Westend; Westend S.A.; Minne Pascal; Invus, L.P.; Invus Public Equities Advisors, LLC","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":138700.0,"shares_display":"138,700","price_per_share":9.6249,"price_display":"9.62","price_state":"stated","total_value":1334973.63,"total_display":"1,334,973.63","total_whole":"1,334,974","shares_owned_after":1688700.0,"shares_owned_after_display":"1,688,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-25","filed_date":"2018-05-30","scope":"insider"},{"id":4069384,"accession":"0000899243-17-026881","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-026881","line_url":"/filing/0000899243-17-026881#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Artal Group S.A.; Invus, L.P.; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Invus Public Equities Advisors, LLC; Minne Pascal","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":9.85,"price_display":"9.85","price_state":"stated","total_value":492500.0,"total_display":"492,500.00","total_whole":"492,500","shares_owned_after":1550000.0,"shares_owned_after_display":"1,550,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-17","filed_date":"2017-11-17","scope":"insider"},{"id":4069380,"accession":"0000899243-17-026881","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-026881","line_url":"/filing/0000899243-17-026881#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Stichting Administratiekantoor Westend; Invus Public Equities, L.P.; Artal Group S.A.; Invus, L.P.; Artal International S.C.A.; Artal International Management S.A.; Westend S.A.; Invus Public Equities Advisors, LLC; Minne Pascal","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":130727.0,"shares_display":"130,727","price_per_share":10.2075,"price_display":"10.21","price_state":"stated","total_value":1334395.8525,"total_display":"1,334,395.85","total_whole":"1,334,396","shares_owned_after":1500000.0,"shares_owned_after_display":"1,500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-15","filed_date":"2017-11-17","scope":"insider"},{"id":5202213,"accession":"0000899243-17-026246","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-17-026246","line_url":"/filing/0000899243-17-026246#line-3","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus Public Equities Advisors, LLC; Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Invus, L.P.; Artal Group S.A.; Artal International Management S.A.; Minne Pascal","owner_display_name":"Invus Public Equities, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":215133.0,"shares_display":"215,133","price_per_share":9.4725,"price_display":"9.47","price_state":"stated","total_value":2037847.3425,"total_display":"2,037,847.34","total_whole":"2,037,847","shares_owned_after":1369273.0,"shares_owned_after_display":"1,369,273","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-14","filed_date":"2017-11-14","scope":"insider"},{"id":5202208,"accession":"0000899243-17-026246","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-17-026246","line_url":"/filing/0000899243-17-026246#line-2","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus Public Equities Advisors, LLC; Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Invus, L.P.; Artal Group S.A.; Artal International Management S.A.; Minne Pascal","owner_display_name":"Invus Public Equities, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":215133.0,"shares_display":"215,133","price_per_share":9.7518,"price_display":"9.75","price_state":"stated","total_value":2097933.9894,"total_display":"2,097,933.99","total_whole":"2,097,934","shares_owned_after":1154140.0,"shares_owned_after_display":"1,154,140","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-13","filed_date":"2017-11-14","scope":"insider"},{"id":5202202,"accession":"0000899243-17-026246","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-026246","line_url":"/filing/0000899243-17-026246#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC.","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Public Equities, L.P.; Stichting Administratiekantoor Westend; Invus Public Equities Advisors, LLC; Westend S.A.; Invus Advisors, L.L.C.; Artal International S.C.A.; Invus, L.P.; Artal Group S.A.; Artal International Management S.A.; Minne Pascal","owner_display_name":"Invus Public Equities, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":145680.0,"shares_display":"145,680","price_per_share":9.7363,"price_display":"9.74","price_state":"stated","total_value":1418384.184,"total_display":"1,418,384.18","total_whole":"1,418,384","shares_owned_after":939007.0,"shares_owned_after_display":"939,007","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-11-10","filed_date":"2017-11-14","scope":"insider"},{"id":2201130,"accession":"0000899243-16-029167","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-029167","line_url":"/filing/0000899243-16-029167#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Blue Buffalo Pet Products, Inc.","issuer_ticker":"BUFF","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Invus, L.P.; Artal International Management S.A.; Westend S.A.; Artal Group S.A.; Stichting Administratiekantoor Westend; Artal International S.C.A.; Invus Advisors, L.L.C.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12512124.0,"shares_display":"12,512,124","price_per_share":24.8273,"price_display":"24.83","price_state":"stated","total_value":310642256.1852,"total_display":"310,642,256.19","total_whole":"310,642,256","shares_owned_after":87460875.0,"shares_owned_after_display":"87,460,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-09-16","filed_date":"2016-09-16","scope":"insider"},{"id":2862676,"accession":"0000899243-16-024751","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-16-024751","line_url":"/filing/0000899243-16-024751#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Blue Buffalo Pet Products, Inc.","issuer_ticker":"BUFF","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal Group S.A.; Westend S.A.; Minne Pascal; Invus, L.P.; Artal International S.C.A.; Artal International Management S.A.; Stichting Administratiekantoor Westend","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15014548.0,"shares_display":"15,014,548","price_per_share":21.285,"price_display":"21.28","price_state":"stated","total_value":319584654.18,"total_display":"319,584,654.18","total_whole":"319,584,654","shares_owned_after":99972999.0,"shares_owned_after_display":"99,972,999","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-07","scope":"insider"},{"id":8233839,"accession":"0000899243-15-001726","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-15-001726","line_url":"/filing/0000899243-15-001726#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"Blue Buffalo Pet Products, Inc.","issuer_ticker":"BUFF","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Artal International Management S.A.; Invus Advisors, L.L.C.; Invus, L.P.; Minne Pascal; Westend S.A.; Stichting Administratiekantoor Westend; Artal Group S.A.; Artal International S.C.A.","owner_display_name":"Artal International Management S.A.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28464603.0,"shares_display":"28,464,603","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":569292060.0,"total_display":"569,292,060.00","total_whole":"569,292,060","shares_owned_after":114987547.0,"shares_owned_after_display":"114,987,547","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-27","filed_date":"2015-07-27","scope":"insider"},{"id":6532377,"accession":"0001209191-14-071632","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-071632","line_url":"/filing/0001209191-14-071632#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Invus Advisors, L.L.C.; Artal International S.C.A.; Stichting Administratiekantoor Westend; Minne Pascal; Artal International Management S.A.; Invus Public Equities, L.P.; Westend S.A.; Artal Group S.A.; Invus Public Equities Advisors, LLC; Invus, L.P.","owner_display_name":"Invus Advisors, L.L.C.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":149253731.0,"shares_display":"149,253,731","price_per_share":1.005,"price_display":"1.00","price_state":"stated","total_value":149999999.655,"total_display":"149,999,999.66","total_whole":"150,000,000","shares_owned_after":149253731.0,"shares_owned_after_display":"149,253,731","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-11-26","filed_date":"2014-11-26","scope":"insider"},{"id":2362109,"accession":"0001181431-12-055549","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-12-055549","line_url":"/filing/0001181431-12-055549#line-1","is_derivative":false,"issuer_cik":"0001053906","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053906","owner_cik":null,"owner_name":"Minne Pascal; Invus Public Equities, L.P.; Invus Public Equities Advisors, LLC; Artal International Management S.A.; Artal International S.C.A.; WESTEND S.A.; Invus, L.P.; Stichting Administratiekantoor Westend; Artal Group S.A.; Invus Advisors, L.L.C.","owner_display_name":"Minne Pascal","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000000.0,"shares_display":"3,000,000","price_per_share":2.25,"price_display":"2.25","price_state":"stated","total_value":6750000.0,"total_display":"6,750,000.00","total_whole":"6,750,000","shares_owned_after":283154744.0,"shares_owned_after_display":"283,154,744","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-10-23","filed_date":"2012-10-25","scope":"insider"},{"id":7585797,"accession":"0001181431-10-017475","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-10-017475","line_url":"/filing/0001181431-10-017475","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"DEBBANE RAYMOND; Invus, L.P.; Invus Advisors, L.L.C.; Ulys, LLC; Invus, CV","owner_display_name":"DEBBANE RAYMOND","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":94270206.0,"shares_display":"94,270,206","price_per_share":1.15,"price_display":"1.15","price_state":"stated","total_value":108410736.9,"total_display":"108,410,736.90","total_whole":"108,410,737","shares_owned_after":130137040.0,"shares_owned_after_display":"130,137,040","ownership_form":"I","is_10b5_1":null,"transaction_date":"2010-03-19","filed_date":"2010-03-19","scope":"insider","n_lines":4},{"id":5800868,"accession":"0001181431-09-047797","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-09-047797","line_url":"/filing/0001181431-09-047797#line-2","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"Invus, L.P.; Ulys, LLC; Invus Advisors, L.L.C.; DEBBANE RAYMOND","owner_display_name":"Invus, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2015888.0,"shares_display":"2,015,888","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":3023832.0,"total_display":"3,023,832.00","total_whole":"3,023,832","shares_owned_after":66949183.0,"shares_owned_after_display":"66,949,183","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-15","filed_date":"2009-10-15","scope":"insider"},{"id":5800865,"accession":"0001181431-09-047797","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-09-047797","line_url":"/filing/0001181431-09-047797#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"Invus, L.P.; Ulys, LLC; Invus Advisors, L.L.C.; DEBBANE RAYMOND","owner_display_name":"Invus, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13439257.0,"shares_display":"13,439,257","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":20158885.5,"total_display":"20,158,885.50","total_whole":"20,158,886","shares_owned_after":64933295.0,"shares_owned_after_display":"64,933,295","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-10-14","filed_date":"2009-10-15","scope":"insider"},{"id":3018307,"accession":"0001181431-08-028285","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-08-028285","line_url":"/filing/0001181431-08-028285#line-1","is_derivative":false,"issuer_cik":"0001053890","issuer_name":"LEXICON PHARMACEUTICALS, INC./DE","issuer_ticker":"LXRX","issuer_name_source":null,"issuer_url":"/issuer/0001053890","owner_cik":null,"owner_name":"Ulys, LLC; Invus Advisors, L.L.C.; Invus, L.P.; DEBBANE RAYMOND","owner_display_name":"Ulys, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":669052.0,"shares_display":"669,052","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":1338104.0,"total_display":"1,338,104.00","total_whole":"1,338,104","shares_owned_after":51494038.0,"shares_owned_after_display":"51,494,038","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-04-30","filed_date":"2008-05-02","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001062822","name":"LEXICON PHARMACEUTICALS, INC.","url":"/issuer/0001062822","role":"Director, Ten percent owner","n_filings":20,"first_seen":"2007-08-24","last_seen":"2023-06-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001609989","name":"Blue Buffalo Pet Products, Inc.","url":"/issuer/0001609989","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2015-07-27","last_seen":"2016-09-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001404570","retrieved_at":"2026-08-22T10:14:19+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}